通过使用双酸盐和RANKL抑制治疗来抑制冠状骨瘤进展
Mélanie Hébert1, Kelly Babic2, Edward C Hsiao3
1Department of Ophthalmology, Hôpital du Saint-Sacrement, CHU de Québec - Université Laval, Québec, Canada.
American journal of ophthalmology case reports
|September 24, 2024
概括
抗骨质结晶药物,包括双酸盐和RANK连接体抑制剂,在稳定胸腔骨质瘤方面表现有前途. 这种治疗可以防止进一步的骨质再吸收,并保护视网膜外层免受缩.
科学领域:
- 眼科医生 眼科 眼科
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 胸腔骨质瘤是罕见的,在胸腔的良性骨化.
- 这些病变可以导致视力丧失通过二次并发症,如视网膜缩.
- 目前对胆管骨质瘤的治疗选择有限,重点是管理并发症.
研究的目的:
- 为了评估抗骨质结晶药物的有效性,在管理胸腔骨质瘤.
- 探索双酸盐和RANK联接体抑制剂作为潜在的治疗剂.
主要方法:
- 一个病例研究,一个患有双侧后胸腔骨质瘤的病人.
- 治疗涉及口服双酸盐 (alendronate) 和皮下RANK连接体抑制剂 (denosumab).
- 药物用于防止再吸收和随后的视网膜损伤.
主要成果:
- 这名患者在9年内通过间歇性抗骨质结晶治疗,表现出胆管骨瘤的稳定.
- 底部摄影,OCT和超声波证实了视网膜和骨瘤厚度和化的稳定性.
- 在治疗期间没有观察到外视网膜缩的显著进展.
结论:
- 抗骨质结晶疗法代表着一种新的治疗方法,用于胸腔骨质瘤.
- 双酸盐和RANK带抑制剂可以防止骨质瘤的再吸收,并保持视觉功能.
- 需要进一步的研究来建立这种治疗范式.
相关概念视频
01:31Osteoclasts in Bone Remodeling
2.8K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.8K
01:27Open Angle Glaucoma: Treatment
406
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
406